If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJpel Priv Eqty Regulatory News (JPEL)

Share Price Information for Jpel Priv Eqty (JPEL)

Share Price is delayed by 15 minutes
Get Live Data
1.24    0.00 (0.00%)
Bid:
1.20
Ask:
1.28
Spread: 0.08 (6.667%)
Market Cap: $21.21m
JPEL Live PriceLast checked at - London Stock Exchange

Intraday Jpel Priv Eqty Share Chart

Significant Investment Progress Announcement

30 Apr 2014 17:03

RNS Number : 9752F
J.P. Morgan Private Equity Ltd
30 April 2014
 

 

SIGNIFICANT INVESTMENT PROGRESS TO DATE

· Invested approximatley $50 million in 4 Companies Since December

· Represents ONE-THIRD OF $150 MILLION of the year-end 2015 Target investment amount

 

GUERNSEY, 30 APRIL 2014

 

In January 2014 JPEL announced that it would seek to invest $150 million through December 2015 in secondary direct deals or concentrated private equity LP positions.

 

JPEL is pleased to announce that with the completion of its fourth investment, it has deployed approximately $50 million of its $150 million investment target. Due to strong distribution flows, JPEL has been able to fund all investments without increasing borrowings under its flexible credit facility.

 

The four investments include:

· In December, JPEL invested approximately $14 million in a US-based tax advisory services firm whose primary business is to provide high-value consulting services relating to government-sponsored tax incentives.

· In February, JPEL invested approximately $14 million in Datamars SA, a leading supplier of animal identification systems (including pet and livestock) and textile identification systems.

· Also in February, JPEL invested approximately $7 million in Placid Holdings, a holding company with an investment in a leading branded Asian handset distributor, with a leading market position in smart phones and feature phones in India.

· In April, JPEL participated in a syndicate of global investors led by Arle Capital to acquire Innovia Group from the Candover 2001 Fund. JPEL invested approximately $14 million in Innovia, an international manufacturer of high quality, speciality films for its key markets of labels, overwrap, packaging and polymer banknote substrate.

 

Each of the four investments share common attributes that JPEL seeks:

· Attractive entry value: On aggregated basis, entry value for the four companies was approximately 6.7x LTM EBITDA and 5.6x 2014P EBITDA

· Manageable leverage: On a weighted average basis, debt at time of investment was approximately 1.8x 2013 LTM EBITDA. 2 of the 4 companies have net cash positions

· High margins: Weighted average LTM EBITDA margins of approximately 25%

· Market leadership: Each of the four companies is a market leader (top 1-3 player) in their respective business segments

· Potential shorter duration: All four companies are existing, mature private equity investments with the potential to be exited in the next 2 to 4 years

· Visible EBITDA growth: Each company projects significant EBITDA growth in the near or mid-term

 

JPEL currently has a very strong investment pipeline and is engaged in due diligence on two potential transactions that could be completed over the next two to three months. Should these investments close, JPEL will have deployed approximately half of its $150 million investment target.

 

 

For further information please contact:

 

J.P. Morgan Private Equity Limited

Greg Getschow

+1 212 648 1150

Gregory.Getschow@jpmorgan.com

 

Rosemary DeRise / Samantha Ladd

+1 212 648 2980 / +1 212 648 2982

Rosemary.DeRise@jpmorgan.com / Samantha.Ladd@jpmorgan.com

 

 

* * *

 

About J.P. Morgan Private Equity Limited

 

J.P. Morgan Private Equity Limited ("JPEL" or the "Company") is a Guernsey registered and incorporated, London Stock Exchange-listed, closed-ended investment company (LSE: JPEL, JPZZ, JPSZ). The Company's capital structure consists of three classes of shares: US$ Equity Shares and two classes of Zero Dividend Preference Shares due 2015 and 2017, respectively.

 

On 15 January 2014, JPEL announced a strategic update, which included plans to maximize net asset value through greater emphasis on JPEL's existing post-credit crisis investment strategy. As part of this update, JPEL announced that it would cease dividend and capital distributions to US$ Equity Shareholders and continue its post-credit crisis investment strategy and will seek to invest $150 million in secondary direct deals or concentrated private equity LP positions. The Company's goal is to create concentrated portfolio to improve ability to assess risk and to increase transparency on underlying portfolio. At the end of the investment period in December 2015, JPEL expects that its top 30 company positions will comprise the majority of its total net asset value.

 

The Company also announced a proposal for the creation of Redeemable Realisation Share Class ("RRS") whereby US$ Equity shareholders would be offered the option to transfer their US$ Equity shares for RRS Shares which will entitle holders to all cash realisations from the Company's investment portfolio in proportion to their aggregate holding within the equity of the Company. This proposal requires shareholder approval and would take effect in 24 months, after the 2015 ZDP Shares are retired.

 

On 15 January 2014, institutional investors purchased 84 million US$ Equity Shares through market purchases at $0.80 per share, an 8.3% premium to the 14 January 2014 share price.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCURRNRSOASOAR
Date   Source Headline
2nd Jun 20269:29 amRNSNet Asset Value - March 2026
23rd Apr 20267:00 amRNSJoint Broker Appointment
14th Apr 20267:00 amRNSAppointment of Directors
6th Mar 20265:59 pmRNSHalf-year Financial Report - December 2025
14th Jan 20269:53 amRNSCOMPLETION OF THIRTEENTH MANDATORY REDEMPTION
29th Dec 20253:18 pmRNSTHIRTEENTH MANDATORY REDEMPTION
19th Dec 20255:53 pmRNSNet Asset Value September 2025
2nd Dec 20254:44 pmRNS2025 AGM Results Statement
10th Nov 202512:19 pmRNS2025 AGM Circular Statement
5th Nov 20254:07 pmRNSHolding(s) in Company
3rd Nov 20254:30 pmRNSHolding(s) in Company
3rd Nov 20254:11 pmRNSHolding(s) in Company
30th Oct 20257:00 amRNSAnnual Financial Report 2025
22nd Jul 20257:00 amRNSAppointed Sole Corp. Broker & Financial Adviser
10th Jun 20254:47 pmRNSNet Asset Value - March 2025
1st May 20256:11 pmRNSHolding(s) in Company
18th Mar 20255:04 pmRNSHalf-year Report - December 2024
3rd Dec 20242:30 pmRNSNet Asset Value September 2024
27th Nov 20245:16 pmRNS2024 AGM Results
6th Nov 20247:00 amRNS2024 AGM Circular
25th Oct 20247:00 amRNSPortfolio Update
25th Oct 20247:00 amRNSAnnual Financial Report - 2024
5th Jun 20247:00 amRNSNet Asset Value - March 2024
23rd Apr 20245:18 pmRNSDirector Declaration
15th Mar 20246:15 pmRNSNet Asset Value - December 2023
15th Mar 20246:03 pmRNSHalf-year Report - December 2023
15th Mar 20243:50 pmRNSHalf-year Report - 2023
6th Dec 20235:36 pmRNSDirector Declaration
6th Dec 20235:33 pmRNSAGM RESULTS 2023
9th Nov 202311:56 amRNS2023 AGM CIRCULAR
8th Nov 20237:00 amRNSCompletion of Twelfth Mandatory Redemption
24th Oct 20237:00 amRNSTwelfth Mandatory Redemption & Shareholder Update
20th Oct 202310:28 amRNSNet Asset Value - September 2023
21st Sep 20235:33 pmRNSNet Asset Value(s) - June 2023
21st Jun 20233:36 pmRNSDirectorate Change
12th May 20231:46 pmRNSNet Asset Value(s) - March 2023
28th Mar 20233:32 pmRNSHalf-year Report - 31 December 2022
14th Mar 20234:35 pmRNSPrice Monitoring Extension
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 202311:05 amRNSSecond Price Monitoring Extn
14th Mar 202311:00 amRNSPrice Monitoring Extension
14th Mar 20239:05 amRNSSecond Price Monitoring Extn
14th Mar 20239:00 amRNSPrice Monitoring Extension
24th Feb 20234:22 pmRNSNet Asset Value(s) - December 2022
13th Feb 20234:51 pmRNSDirector Declaration
22nd Dec 20227:00 amRNSCompletion of Eleventh Mandatory Redemption
14th Dec 20227:00 amRNSELEVENTH MANDATORY REDEMPTION & SHAREHOLDER UPDATE
13th Dec 20225:09 pmRNSDirectorate Change
29th Nov 20224:33 pmRNSAGM Results 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.